Eurofins announces the success of its tender offer on its €400m hybrid bond


3 April 2025

Eurofins Scientific (EUFI.PA, rated Baa3 by Moody’s and BBB- by Fitch, “Eurofins”), a global leader in bioanalytical
testing, announces today the results of the tender offer (the “Tender Offer”) in respect of its €400m 3.250% hybrid
bond (ISIN: XS1716945586) issued on 13 November 2017 with a first call date on 13 November 2025 (the “2025
Hybrid Bond”).

At the expiration deadline of the Tender Offer (2 April 2025, 5pm CEST), Eurofins had received valid tenders of
€194m in aggregate principal amount of the 2025 Hybrid Bond.

Eurofins has decided to accept all valid tenders for purchase (all amounts in EUR):

Current Outstanding Bond Validly Tendered Bond Accepted for Remaining Outstanding
Purchase

400,000,000 193,978,000 193,978,000 206,022,000


Settlement of the purchase is expected to take place on 7 April 2025 (the “Settlement Date”).

With this Tender Offer, together with the recent issuance of the new 2032 hybrid bond announced on last 27 March
2025, Eurofins has proactively managed the refinancing of its outstanding hybrid bonds.

Notes to Editors:

For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com



About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins Scientific S.E. network of independent companies believes that it is a global leader in
food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material
sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory
services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing.
It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic
products.



Eurofins Scientific 1/2 April 2025
With ca. 63,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000
companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity,
composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical
diagnostic testing services and in-vitro diagnostic products.

Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our
objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible
turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety
standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners
around the world.

The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology
portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field
of biotechnology and analytical chemistry to offer their clients unique analytical solutions.

Shares in Eurofins Scientific S.E. are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA,
Bloomberg ERF FP).




Until it has been lawfully made public widely by Eurofins Scientific S.E. through approved distribution channels, this document
contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16
April 2014 on market abuse, as amended.

Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of Eurofins Scientific S.E.’s management as of the date of
this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events
discussed in this release may not occur. Eurofins Scientific S.E. disclaims any intent or obligation to update any of these
forward-looking statements and estimates. All statements and estimates are made based on the information available to the
Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.




Eurofins Scientific 2/2 April 2025